...
首页> 外文期刊>Oxford Medical Case Reports >Poorly differentiated adenocarcinoma of an unknown primary with a thyroid tumour and an aggressive course: thyroid or lung carcinoma?
【24h】

Poorly differentiated adenocarcinoma of an unknown primary with a thyroid tumour and an aggressive course: thyroid or lung carcinoma?

机译:原发性不明的甲状腺癌低分化腺癌,伴甲状腺癌或肺癌?

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Cancers of unknown primary (CUPs) are challenging for physicians to diagnose and treat. Metastases to the thyroid gland are rare, representing less than 1% of all thyroid malignancies. Here, we report a case of a 69-year-old Asian man who had both thyroid gland and lymph node enlargement in the neck and shoulders but no nodules/tumours in the lung field. The patient died 51 days after his first visit to our office, although pembrolizumab was administered on day 34 based on programmed cell death-ligand 1 (PD-L1) expression. Immunohistochemistry (IHC) with paired box 8 (PAX8) may be useful to diagnostically distinguish poorly differentiated lung adenocarcinomas from napsin A-positive thyroid carcinomas.
机译:未知原发性癌症(CUP)对医生的诊断和治疗具有挑战性。甲状腺转移很少见,占所有甲状腺恶性肿瘤的不到1%。在这里,我们报告了一例69岁的亚洲男子,他的颈部和肩部都有甲状腺和淋巴结肿大,而在肺野却没有结节/肿瘤。尽管根据程序性细胞死亡配体1(PD-L1)表达在第34天给予了pembrolizumab,但患者在首次访问我们的办公室后51天死亡。带有配对框8(PAX8)的免疫组织化学(IHC)可能在诊断上将低分化的肺腺癌与餐巾A阳性甲状腺癌区分开来。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号